Skip to main content

Advertisement

SpringerLink
Log in

Diagnostic values of ischemia modified albumin in diabetes-related complications: a narrative review

  • Review article
  • Published:
Journal of Diabetes & Metabolic Disorders Aims and scope Submit manuscript

Abstract

Purpose

Oxidative stress (OS) plays a critical role in the onset and progression of macro and microvascular complications of diabetes mellitus (DM). Ischemia-modified albumin (IMA) is a novel and simple test for evaluating OS. In the present study, we reviewed the available information on the alteration of circulating IMA in DM and its possible prognostic and diagnostic value in DM-related complications.

Methods

Relevant studies regarding IMA alteration in DM published until May 30, 2022 were extracted from Google Scholar, PubMed, Scopus, and Science Direct databases. The following key words were used: IMA, DM, diabetes complications, retinopathy, nephropathy, diabetic foot, and vascular complications.

Results

This review revealed increased circulating IMA levels in the patients with type 1, type 2, and gestational DM. Furthermore, IMA showed a close relationship with the severity of DM complications including hyperglycemia, dyslipidemia, diabetic retinopathy, diabetic nephropathy, peripheral arterial disease, and diabetic foot ulcer. However, lack of assay standardization and low specificity are major obstacles to the use of IMA as a promising biomarker.

Conclusion

IMA levels are associated with DM complications and can be applied as a practical test for evaluating the risk and predicting the severity of DM complications.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183: 109119. https://doi.org/10.1016/j.diabres.2021.109119.

    Article  PubMed  Google Scholar 

  2. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas. Diabetes Res Clin Pract. 2019;157: 107843. https://doi.org/10.1016/j.diabres.2019.107843.

    Article  PubMed  Google Scholar 

  3. Poznyak A, Grechko AV, Poggio P, Myasoedova VA, Alfieri V, Orekhov AN. The diabetes mellitus–atherosclerosis connection: The role of lipid and glucose metabolism and chronic inflammation. Int J Mol Sci. 2020;21(5):1835. https://doi.org/10.3390/ijms21051835.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Savelieff MG, Callaghan BC, Feldman EL. The emerging role of dyslipidemia in diabetic microvascular complications. Curr Opin Endocrinol Diabetes Obes. 2020;27(2):115–23. https://doi.org/10.1097/MED.0000000000000533.

    Article  CAS  PubMed  Google Scholar 

  5. Dos Santos JM, Tewari S, Mendes RH. The role of oxidative stress in the development of diabetes mellitus and its complications. J Diabetes Res. 2019;2019(5):4189813. https://doi.org/10.1155/2019/4189813.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Tampa M, Mitran CI, Mitran MI, Amuzescu A, Matei C, Georgescu SR. Ischemia-Modified Albumin-A Potential New Marker of Oxidative Stress in Dermatological Diseases. Medicina (Kaunas). 2022;58(5):669. https://doi.org/10.3390/medicina58050669.

    Article  PubMed  Google Scholar 

  7. Reddy SV, Munikumar M, Duggina P, Varma N. A diagnostic test accuracy meta-analysis of maternal serum ischemia-modified albumin for detection of preeclampsia. J Matern Fetal Neonatal Med. 2019;32(13):2173–81. https://doi.org/10.1080/14767058.2018.1427724.

    Article  CAS  Google Scholar 

  8. Shin H, Kim JG, Jang BH, Lim TH, Kim W, Cho Y, et al. Diagnostic Accuracy of Ischemia-Modified Albumin for Acute Coronary Syndrome: A Systematic Review and Meta-Analysis. Medicina (Kaunas). 2022;58(5):614. https://doi.org/10.3390/medicina58050614.

    Article  PubMed  Google Scholar 

  9. Mangoni AA, Zinellu A. A Systematic Review and Meta-Analysis of Serum Concentrations of Ischaemia-Modified Albumin in Acute Ischaemic Stroke, Intracerebral Haemorrhage, and Subarachnoid Haemorrhage. Biomolecules. 2022;12(5):653. https://doi.org/10.3390/biom12050653.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Sinha M, Vazquez J, Calvino R, Gaze D, Collinson P, Kaski J. Effects of balloon occlusion during percutaneous coronary intervention on circulating ischemia modified albumin and transmyocardial lactate extraction. Heart. 2006;92(12):1852–3. https://doi.org/10.1136/hrt.2005.078089.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Bar-Or D, Winkler JV, VanBenthuysen K, Harris L, Lau E, Hetzel FW. Reduced albumin-cobalt binding with transient myocardial ischemia after elective percutaneous transluminal coronary angioplasty: a preliminary comparison to creatine kinase-MB, myoglobin, and troponin I. Am Heart J. 2001;141(6):985–91. https://doi.org/10.1067/mhj.2001.114800.

    Article  CAS  PubMed  Google Scholar 

  12. Bakula M, Milicevic G, Kozic I, Rumenjak V, Dominkovic A. Kinetics of Ischemia-Modified Albumin Following Exercise-Induced Myocardial Ischemia. Clin Lab. 2016;62(4):563–71. https://doi.org/10.7754/clin.lab.2015.150732.

    Article  CAS  PubMed  Google Scholar 

  13. Bhagavan NV, Lai EM, Rios PA, Yang J, Ortega-Lopez AM, Shinoda H, et al. Evaluation of human serum albumin cobalt binding assay for the assessment of myocardial ischemia and myocardial infarction. Clin Chem. 2003;49(4):581–5. https://doi.org/10.1373/49.4.581.

    Article  CAS  PubMed  Google Scholar 

  14. Kaefer M, Piva SJ, De Carvalho JA, Da Silva DB, Becker AM, Coelho AC, et al. Association between ischemia modified albumin, inflammation and hyperglycemia in type 2 diabetes mellitus. Clin Biochem. 2010;43(4–5):450–4. https://doi.org/10.1016/j.clinbiochem.2009.11.018.

    Article  CAS  PubMed  Google Scholar 

  15. Dayanand C, Vegi PK, Lakshmaiah V, Kutty A. Association of ischemia modified albumin in terms of hypoxic risk with carbonylated protein, glycosylated hemoglobin and plasma insulin in type 2 diabetes mellitus. Int J Biotech Biochem. 2013;9(3):275–84.

    Google Scholar 

  16. Chawla R, Loomba R, Guru D, Loomba V. Ischemia Modified Albumin (IMA) - A Marker of Glycaemic Control and Vascular Complications in Type 2 Diabetes Mellitus. J Clin Diagn Res. 2016;10(3):BC13-6. https://doi.org/10.7860/JCDR/2016/15282.7432.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Setoodeh S, Khorsand M, Takhshid MA. The effects of iron overload, insulin resistance and oxidative stress on metabolic disorders in patients with beta- thalassemia major. J Diabetes Metab Disord. 2020;19(2):767–74. https://doi.org/10.1007/s40200-020-00560-x.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Keshavarzi F, Rastegar M, Vessal M, Rafiei Dehbidi G, Khorsand M, Ganjkarimi AH, Takhshid MA. Serum ischemia modified albumin is a possible new marker of oxidative stress in phenylketonuria. Metab Brain Dis. 2018;33(3):675–80. https://doi.org/10.1007/s11011-017-0165-3.

    Article  CAS  PubMed  Google Scholar 

  19. Oh BJ, Seo M-H, Kim H-S. Insignificant role of the N-terminal cobalt-binding site of albumin in the assessment of acute coronary syndrome: discrepancy between the albumin cobalt-binding assay and N-terminal-targeted immunoassay. Biomarkers. 2012;17(5):394–401. https://doi.org/10.3109/1354750X.2012.672460.

    Article  CAS  PubMed  Google Scholar 

  20. Lippi G, Salvagno GL, Montagnana M, Schena F, Ballestrieri F, Guidi GC. Influence of physical exercise and relationship with biochemical variables of NT-pro-brain natriuretic peptide and ischemia modified albumin. Clin Chim Acta. 2006;367(1–2):175–80. https://doi.org/10.1016/j.cca.2005.11.018.

    Article  CAS  PubMed  Google Scholar 

  21. Lippi G, Montagnana M, Salvagno GL, Guidi GC. Standardization of ischemia-modified albumin testing: adjustment for serum albumin. Clin Chem Lab Med. 2007;45(2):261–2. https://doi.org/10.1515/CCLM.2007.039.2007.

    Article  CAS  PubMed  Google Scholar 

  22. Lee E, Eom J-E, Jeon K-H, Kim TH, Kim E, Jhon G-J, et al. Evaluation of albumin structural modifications through cobalt-albumin binding (CAB) assay. J Pharm Biomed Anal. 2014;91:17–23. https://doi.org/10.1016/j.jpba.2013.12.003.

    Article  CAS  PubMed  Google Scholar 

  23. Ahmad A, Manjrekar P, Yadav C, Agarwal A, Srikantiah RM, Hegde A. Evaluation of Ischemia-Modified Albumin, Malondialdehyde, and Advanced Oxidative Protein Products as Markers of Vascular Injury in Diabetic Nephropathy. Biomark Insights. 2016;11:63–8. https://doi.org/10.4137/BMI.S39053.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Shevtsova A, Gordiienko I, Tkachenko V, Ushakova G. Ischemia-Modified Albumin: Origins and Clinical Implications. Dis Markers. 2021;2021(19):9945424. https://doi.org/10.1155/2021/9945424.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Refaat S, Abd El-Ghaffar N, Khalil A. The relationship between ischemia modified albumin and lipids in type 2 Egyptian diabetic patients. Adv Biol Res. 2014;8:18–22.

    Google Scholar 

  26. Piwowar A, Knapik-Kordecka M, Warwas M. Ischemia-modified albumin level in type 2 diabetes mellitus - Preliminary report. Dis Markers. 2008;24(6):311–7. https://doi.org/10.1155/2008/784313.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Sushith S, Krishnamurthy HN, Reshma S, Janice D, Madan G, Ashok KJ, et al. Serum Ischemia-Modified Albumin, Fibrinogen, High Sensitivity C- Reactive Proteins in Type-2 Diabetes Mellitus without Hypertension and Diabetes Mellitus with Hypertension: A Case-Control Study. Rep Biochem Mol Biol. 2020;9(2):241–9. https://doi.org/10.29252/rbmb.9.2.241.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Guerin-Dubourg A, Cournot M, Planesse C, Debussche X, Meilhac O, Rondeau P, et al. Association between Fluorescent Advanced Glycation End-Products and Vascular Complications in Type 2 Diabetic Patients. Biomed Res Int. 2017;2017:7989180. https://doi.org/10.1155/2017/7989180.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Kurt HA, Demirci E, Alan C. Endothelial Dysfunction and Ischemia-Modified Albumin Levels in Males with Diabetic and Nondiabetic Erectile Dysfunction. Dis Markers. 2022;2022(9):3661822. https://doi.org/10.1155/2022/3661822.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Reddy VS, Agrawal P, Sethi S, Gupta N, Garg R, Madaan H, et al. Associations of FPG, A1C and disease duration with protein markers of oxidative damage and antioxidative defense in type 2 diabetes and diabetic retinopathy. Eye (Lond). 2015;29(12):1585–93. https://doi.org/10.1038/eye.2015.177 (Epub 2015 Sep).

    Article  CAS  PubMed  Google Scholar 

  31. Dahiya K, Aggarwal K, Seth S, Singh V, Sharma TK. Type 2 diabetes mellitus without vascular complications and ischemia modified albumin. Clin Lab. 2010;56(5–6):187–90.

    CAS  PubMed  Google Scholar 

  32. Kopin L, Lowenstein CJ. Dyslipidemia. Annals of internal medicine. Ann Intern Med. 2017;167(11):ITC81–96. https://doi.org/10.7326/AITC201712050.

    Article  PubMed  Google Scholar 

  33. El-Eshmawy MM, Gad DF, El-Baiomy AA. Elevated Serum Levels of Ischemia Modified Albumin and Malondialdehyde are Related to Atherogenic Index of Plasma in a Cohort of Prediabetes. Endocr Metab Immune Disord Drug Targets. 2020;20(8):1347–54. https://doi.org/10.2174/1871530320666200503052226.

    Article  CAS  PubMed  Google Scholar 

  34. Valle Gottlieb MG, da Cruz IB, Duarte MM, Moresco RN, Wiehe M, Schwanke CH, et al. Associations among metabolic syndrome, ischemia, inflammatory, oxidatives, and lipids biomarkers. J Clin Endocrinol Metab. 2010;95(2):586–91. https://doi.org/10.1210/jc.2009-1592.

    Article  CAS  PubMed  Google Scholar 

  35. Incel-Uysal P, Akdogan N, Alli N, Oktem A, Candar T, Topcuoglu C, et al. Assessment of Metabolic Profile and Ischemia-modified Albumin Level in Patients with Alopecia Areata: A Case-Control Study. Indian J Dermatol. 2019;64(1):12–8. https://doi.org/10.4103/ijd.IJD_238_18.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Han K, Jia N, Yang L, Min LQ. Correlation between ischemia-modified albumin and lipid levels in patients with acute cerebrovascular disease. Mol Med Rep. 2012;6(3):621–4. https://doi.org/10.3892/mmr.2012.961.

    Article  CAS  PubMed  Google Scholar 

  37. Kjeldsen SE. Hypertension and cardiovascular risk: General aspects. Pharmacol Res. 2018;129:95–9. https://doi.org/10.1016/j.phrs.2017.11.003.

    Article  PubMed  Google Scholar 

  38. Yazici MU, Ayar G, Savas-Erdeve S, Azapagasi E, Neselioglu S, Erel O, et al. Role of Ischemia Modified Albumin Serum Levels as an Oxidative Stress Marker in Children with Diabetic Ketoacidosis. Comb Chem High Throughput Screen. 2019;22(8):577–81. https://doi.org/10.2174/1386207322666191008214919.

    Article  CAS  PubMed  Google Scholar 

  39. Ma SG, Jin Y, Xu W, Hu W, Bai F, Wu XJ. Increased serum levels of ischemia-modified albumin and C-reactive protein in type 1 diabetes patients with ketoacidosis. Endocrine. 2012;42(3):570–6. https://doi.org/10.1007/s12020-012-9652-9.

    Article  CAS  PubMed  Google Scholar 

  40. Rossi A, Bortolotti N, Vescovo S, Romanello I, Forzano L, Londero AP, et al. Ischemia-modified albumin in pregnancy. Eur J Obstet Gynecol Reprod Biol. 2013;170(2):348–51. https://doi.org/10.1016/j.ejogrb.2013.06.037.

    Article  CAS  PubMed  Google Scholar 

  41. Bahinipati J, Mohapatra PC. Ischemia modified albumin as a marker of oxidative stress in normal pregnancy. J Clin Diagn Res. 2016;10(9):BC15–7. https://doi.org/10.7860/JCDR/2016/21609.8454.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Ma S-g, Yu W-n, Jin Y, Hong B, Hu W. Evaluation of serum ischemia-modified albumin levels in pregnant women with and without gestational diabetes mellitus. Gynecol Endocrinol. 2012;28(11):837–40. https://doi.org/10.3109/09513590.2012.683069.

    Article  CAS  PubMed  Google Scholar 

  43. Mohsen L, Akmal DM, Ghonaim EKE, Riad NM. Role of mean platelet volume and ischemia modified albumin in evaluation of oxidative stress and its association with postnatal complications in infants of diabetic mothers. J Matern Fetal Neonatal Med. 2018;31(14):1819–23. https://doi.org/10.1080/14767058.2017.1330329.

    Article  CAS  PubMed  Google Scholar 

  44. Topaloglu N, Yildirim S, Tekin M, Kaymaz N, Tutunculer F, Ozdemir C, et al. Mean platelet volume and ischemia modified albumin levels in cord blood of infants of diabetic mothers. Pediatr Neonatol. 2014;55(6):455–8. https://doi.org/10.1016/j.pedneo.2014.02.002.

    Article  PubMed  Google Scholar 

  45. Ozdemir OM, Ozdemir E, Enli Y, Oztekin O, Ergin H. Ischemia-modified albumin in preterm infants born to mothers with pre-eclampsia. Pediatr Int. 2018;60(6):553–9. https://doi.org/10.1111/ped.13563.

    Article  CAS  PubMed  Google Scholar 

  46. Viigimaa M, Sachinidis A, Toumpourleka M, Koutsampasopoulos K, Alliksoo S, Titma T. Macrovascular complications of type 2 diabetes mellitus. Curr Vasc Pharmacol. 2020;18(2):110–6. https://doi.org/10.2174/1570161117666190405165151.

    Article  CAS  PubMed  Google Scholar 

  47. Libby P. The changing landscape of atherosclerosis. Nature. 2021;592(7855):524–33. https://doi.org/10.1038/s41586-021-03392-8.

    Article  CAS  PubMed  Google Scholar 

  48. D’souza JM, D’souza RP, Vijin VF, Shetty A, Arunachalam C, Pai VR, et al. High predictive ability of glycated hemoglobin on comparison with oxidative stress markers in assessment of chronic vascular complications in type 2 diabetes mellitus. Scand J Clin Lab Invest. 2016;76(1):51–7. https://doi.org/10.3109/00365513.2015.1092048.

    Article  CAS  PubMed  Google Scholar 

  49. Xiang L, Zhang M, Wu H, Xie D. The expression and prognostic value of ischemia modified albumin (IMA), red blood cell distribution width (RDW), and lipoprotein (LP) in patients with diabetes mellitus complicated with coronary heart disease. Ann Palliat Med. 2021;10(4):4463–71. https://doi.org/10.21037/apm-21-425.

    Article  PubMed  Google Scholar 

  50. Cournot M, Burillo E, Saulnier PJ, Planesse C, Gand E, Rehman M, et al. Circulating Concentrations of Redox Biomarkers Do Not Improve the Prediction of Adverse Cardiovascular Events in Patients with Type 2 Diabetes Mellitus. J Am Heart Assoc. 2018;7(5): e007397. https://doi.org/10.1161/JAHA.117.007397.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Yang SL, Zhu LY, Han R, Sun LL, Li JX, Dou JT. Pathophysiology of peripheral arterial disease in diabetes mellitus. J Diabetes. 2017;9(2):133–40. https://doi.org/10.1111/1753-0407.12474.

    Article  CAS  PubMed  Google Scholar 

  52. Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, et al. 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2017;69(11):e71–126. https://doi.org/10.1016/j.jacc.2016.11.007.

    Article  PubMed  Google Scholar 

  53. Haigh K, Bingley J, Golledge J, Walker PJ. Peripheral arterial disease: screening in general practice. Aust Fam Physician. 2013;42(6):391–5.

    PubMed  Google Scholar 

  54. Nicolaï SP, Kruidenier LM, Rouwet EV, Bartelink M-LE, Prins MH, Teijink JA. Ankle brachial index measurement in primary care: are we doing it right? Br J Gen Pract. 2009;59(563):422–7. https://doi.org/10.3399/bjgp09X420932.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Pan C-R, Staessen JA, Li Y, Wang J-G. Comparison of three measures of the ankle-brachial blood pressure index in a general population. Hypertens Res. 2007;30(6):555–61. https://doi.org/10.1291/hypres.30.555.

    Article  PubMed  Google Scholar 

  56. Alqahtani KM, Bhangoo M, Vaida F, Denenberg JO, Allison MA, Criqui MH. Predictors of change in the ankle brachial index with exercise. Eur J Vasc Endovasc Surg. 2018;55(3):399–404. https://doi.org/10.1016/j.ejvs.2017.12.004.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Aboyans V, Criqui MH, Abraham P, Allison MA, Creager MA, Diehm C, et al. Measurement and interpretation of the ankle-brachial index: a scientific statement from the American Heart Association. Circulation. 2012;126(24):2890–909. https://doi.org/10.1161/CIR.0b013e318276fbcb.

    Article  PubMed  Google Scholar 

  58. Fort-Gallifa I, García-Heredia A, Hernández-Aguilera A, Simó JM, Sepúlveda J, Martín-Paredero V, et al. Biochemical indices of oxidative stress and inflammation in the evaluation of peripheral artery disease. Free Radic Biol Med. 2016;97:568–76. https://doi.org/10.1016/j.freeradbiomed.2016.07.011.

    Article  CAS  PubMed  Google Scholar 

  59. Stone PA, Yacoub M, editors. Inflammatory biomarkers in peripheral arterial disease. Semin Vasc Surg 2014;27(3-4):148-51. https://doi.org/10.1053/j.semvascsurg.2015.01.009.

  60. Ma SG, Wei CL, Hong B, Yu WN. Ischemia-modified albumin in type 2 diabetic patients with and without peripheral arterial disease. Clinics (Sao Paulo). 2011;66(10):1677–80. https://doi.org/10.1590/s1807-59322011001000003.

    Article  PubMed  Google Scholar 

  61. Nativel M, Schneider F, Saulnier PJ, Gand E, Ragot S, Meilhac O, et al. Prognostic Values of Inflammatory and Redox Status Biomarkers on the Risk of Major Lower-Extremity Artery Disease in Individuals with Type 2 Diabetes. Diabetes Care. 2018;41(10):2162–9. https://doi.org/10.2337/dc18-0695.

    Article  CAS  PubMed  Google Scholar 

  62. Feng F, Chen Y, Wang G, Huang P, Zhu Q, Zhou B. Correlation of Serum CysC, IMA, and LP-PLA2 Levels with Type 2 Diabetes Mellitus Patients with Lower Extremity Atherosclerotic Occlusive Disease. Front Surg. 2022;9(9): 846470. https://doi.org/10.3389/fsurg.2022.846470.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Igari K, Kudo T, Toyofuku T, Inoue Y. The relationship between endothelial dysfunction and endothelial cell markers in peripheral arterial disease. PLoS One. 2016;11(11):e0166840. https://doi.org/10.1371/journal.pone.0166840.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Balamir I, Ates I, Topcuoglu C, Turhan T. Association of Endocan, Ischemia-Modified Albumin, and hsCRP Levels with Endothelial Dysfunction in Type 2 Diabetes Mellitus. Angiology. 2018;69(7):609–16. https://doi.org/10.1177/0003319717740781.

    Article  CAS  PubMed  Google Scholar 

  65. Wang Y, Shao T, Wang J, Huang X, Deng X, Cao Y, et al. An update on potential biomarkers for diagnosing diabetic foot ulcer at early stage. Biomed Pharmacother. 2021;133: 110991. https://doi.org/10.1016/j.biopha.2020.110991.

    Article  CAS  PubMed  Google Scholar 

  66. Muhtaroglu S, Barlak Keti D, Unluhizarci K. Investigation of ischemia-modified albumin levels and some atherosclerosis-related serum parameters in patients with diabetic foot. Turk J Med Sci. 2016;46(1):126–32. https://doi.org/10.3906/sag-1406-38.

    Article  CAS  PubMed  Google Scholar 

  67. Alay H, Laloglu E, Kesmez Can F. An evaluation of ischaemia-modified albumin levels in the development of diabetic foot ulcer. Int J Clin Pract. 2021;75(9):e14589. https://doi.org/10.1111/ijcp.14589.

    Article  CAS  PubMed  Google Scholar 

  68. Ozkan S, Adanas C, Alp HH. Is ischaemia-modified albumin a biomarker in wagner classification in diabetic foot ulcers? Int J Clin Pract. 2021;75(12): e14830. https://doi.org/10.1111/ijcp.14830.

    Article  CAS  PubMed  Google Scholar 

  69. Afrah H, Sridhar R, Sushith S, Balakrishna PM, Hanumanthappa M, Srinivasan MP, et al. Evaluation of Ischemia-Modified Albumin and Fibrinogen in Relation with High-Sensitive C-reactive Protein in Diabetic Foot Ulcers. J Diabetes Endocr Pract. 2020;03(02):70–4. https://doi.org/10.4103/jdep.jdep_15_19.

    Article  Google Scholar 

  70. Ahmad A, Ahsan H. Biomarkers of inflammation and oxidative stress in ophthalmic disorders. J Immunoassay Immunochem. 2020;41(3):257–71. https://doi.org/10.1080/15321819.2020.1726774.

    Article  CAS  PubMed  Google Scholar 

  71. Jia ZT, Liu CY, Li H. Changes of the concentration of serum ischemia modified albumin and high sensitivity C-reactive protein in type 2 diabetic patients with retinopathy. Zhonghua Yan Ke Za Zhi. 2009;45(9):805–8.

    CAS  PubMed  Google Scholar 

  72. Turk A, Nuhoglu I, Mentese A, Karahan SC, Erdol H, Erem C. The relationship between diabetic retinopathy and serum levels of ischemia-modified albumin and malondialdehyde. Retina. 2011;31(3):602–8. https://doi.org/10.1097/IAE.0b013e3181ed8cd1.

    Article  CAS  PubMed  Google Scholar 

  73. Reddy VS, Sethi S, Agrawal P, Gupta N, Garg R. Ischemia modified albumin (IMA) and albumin adjusted-IMA (AAIMA) as biomarkers for diabetic retinopathy. Nepal J Ophthalmol. 2015;7(14):117–23. https://doi.org/10.3126/nepjoph.v7i2.14960.

    Article  PubMed  Google Scholar 

  74. Ghosh K, Muddeshwar MG, Ghosh K. Ischemia Modified Albumin Test to Detect Early Diabetic Complications. Am J Med Sci. 2017;354(5):467–70. https://doi.org/10.1016/j.amjms.2017.06.017.

    Article  PubMed  Google Scholar 

  75. Kirboga K, Ozec AV, Kosker M, Dursun A, Toker MI, Aydin H, et al. The Association between Diabetic Retinopathy and Levels of Ischemia-Modified Albumin, Total Thiol, Total Antioxidant Capacity, and Total Oxidative Stress in Serum and Aqueous Humor. J Ophthalmol. 2014;2014: 820853. https://doi.org/10.1155/2014/820853.

    Article  PubMed  PubMed Central  Google Scholar 

  76. Mertoglu C, Siranli G, Coban TA, Karakurt Y, Ersoy A, Ozcicek A, et al. The role of protein oxidation in the development of diabetic microvascular complications. North Clin Istanb. 2021;8(5):500–6. https://doi.org/10.14744/nci.2021.33341.

    Article  PubMed  PubMed Central  Google Scholar 

  77. Gulpamuk B, Tekin K, Sonmez K, Inanc M, Neselioglu S, Erel O, et al. The significance of thiol/disulfide homeostasis and ischemia-modified albumin levels to assess the oxidative stress in patients with different stages of diabetes mellitus. Scand J Clin Lab Invest. 2018;78(1–2):136–42. https://doi.org/10.1080/00365513.2017.1422540.

    Article  CAS  PubMed  Google Scholar 

  78. Kumar W, Martins RS, Anjum N, Fatima SS. Ischemia modified albumin as a useful marker for diagnoses and management of diabetic retinopathy. Pak J Med Sci. 2022;38(4Part-II):1043–7. https://doi.org/10.12669/pjms.38.4.4813.

    Article  PubMed  PubMed Central  Google Scholar 

  79. Soiberman U, Levy R, Schwartz S, Goldstein M, Loewenstein A, Barak A. Serum ischemia modified albumin and vascular endothelial growth factor levels following intravitreal bevacizumab injections. Eur J Ophthalmol. 2014;24(4):570–5. https://doi.org/10.5301/ejo.5000408.

    Article  PubMed  Google Scholar 

  80. Ukinc K, Eminagaoglu S, Ersoz HO, Erem C, Karahan C, Hacihasanoglu AB, et al. A novel indicator of widespread endothelial damage and ischemia in diabetic patients: ischemia-modified albumin. Endocrine. 2009;36(3):425–32. https://doi.org/10.1007/s12020-009-9236-5.

    Article  CAS  PubMed  Google Scholar 

  81. Piwowar A, Knapik-Kordecka M, Warwas M. Comparison of the usefulness of plasma levels of oxidatively modified forms of albumin in estimating kidney dysfunction in diabetic patients. Clin Invest Med. 2010;33(2):E109. https://doi.org/10.25011/cim.v33i2.12349.

    Article  CAS  PubMed  Google Scholar 

  82. Inci A, Olmaz R, Sari F, Coban M, Ellidag HY, Sarikaya M. Increased oxidative stress in diabetic nephropathy and its relationship with soluble Klotho levels. Hippokratia. 2016;20(3):198–203.

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This study was supported by a grant from the Vice-Chancellor for Research Affairs of Shiraz University of Medical Sciences, Shiraz, Iran. The authors wish to thank Dr. Laleh Khojasteh and Sepideh Namdari for their invaluable assistance in editing this manuscript.

Author information

Authors and Affiliations

  1. Laboratory Sciences Department, Faculty of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran

    Oranoos Ghareghani, Shagayegh Ghareghani & Mohammad Ali Takhshid

  2. Diagnostic Laboratory Sciences and Technology Research Center, Faculty of Paramedical Sciences, Shiraz University of Medical Sciences, Meshkinfam Street, Shiraz, Iran

    Mohammad Ali Takhshid

Authors
  1. Oranoos Ghareghani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shagayegh Ghareghani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mohammad Ali Takhshid
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mohammad Ali Takhshid.

Ethics declarations

Conflict of interest

No competing financial interests exist.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ghareghani, O., Ghareghani, S. & Takhshid, M.A. Diagnostic values of ischemia modified albumin in diabetes-related complications: a narrative review. J Diabetes Metab Disord 22, 35–46 (2023). https://doi.org/10.1007/s40200-022-01152-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40200-022-01152-7

Keywords

Search

Navigation